NCT00503243 · Interventional trial
Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) vs SPD476 Given as a Single Dose (4.8 g/Day) in Subjects With Acute Mild to Moderate Ulcerative Colitis
Overall registry status Completed
Phase 3
Conditions Colitis, Ulcerative
Delaware Valley sites
- University of Pennsylvania · Philadelphia, PA · Philadelphia County
First posted
Registry updated
Added to the directory